THE EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) ON RAT MODELS OF DEPRESSION
Funder
National Health and Medical Research Council
Funding Amount
$204,274.00
Summary
Repetitive Transcranial Magnetic Stimulation (rTMS) is the direct stimulation of the brain by using high field magnetic pulses. It is a new technique that has been demonstrated to have some potential as a treatment of depressive illness and possibly other neuropsychiatric disorders. At this early stage of its investigation, the parameters of stimulation that are most likely to be therapeutic, and its mechanisms of action, are not known. Published studies vary in the frequency, duration and exten ....Repetitive Transcranial Magnetic Stimulation (rTMS) is the direct stimulation of the brain by using high field magnetic pulses. It is a new technique that has been demonstrated to have some potential as a treatment of depressive illness and possibly other neuropsychiatric disorders. At this early stage of its investigation, the parameters of stimulation that are most likely to be therapeutic, and its mechanisms of action, are not known. Published studies vary in the frequency, duration and extent of stimulation, with no firm guidelines about optimal parameters. Empirical study of the relative effects of stimulation at different frequencies, at different numbers of stimuli and for different durations is therefore important for the future development of this treatment. Such an investigation is best carried out in an animal model of depression for both ethical and practical reasons, as such studies in patients would possibly take many years and be extremely difficult to conduct. We propose such a study in rat models of depression which have demonstrated validity and utility in drug research. Rat models have a long track record in developing psychiatric treatments and are cost-effective and of proven value. We also plan to investigate the neuroanatomy of the immediate-early genes induced by TMS and compare it with electroconvulsive shock (ECS) and a tricyclic antidepressant, two established treatments of depression. The results will have implications for future human studies in guiding us toward the optimal parameters for therapeutic effects. They will also enhance our understanding of the mechanism of action of TMS in depression.Read moreRead less
Developing New Treatment Approaches For Severe And Treatment Resistant Depression
Funder
National Health and Medical Research Council
Funding Amount
$2,060,520.00
Summary
Depression is a common, disabling problem. One third of depressed patients do not respond to treatment with standard medications and psychological therapy. This research program will focus on developing new treatment approaches for these people: optimising electroconvulsive therapy, a highly effective treatment, developing new non invasive brain stimulation treatments, generating new knowledge on how best to use ketamine treatment.
Australasian Partnership For Improving Outcomes In Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$909,752.00
Summary
This 5-year project examines how proven treatments are used in real-world clinical practice, and how this can be improved. The project focuses on important physical interventions for depression: Electroconvulsive therapy (ECT), Ketamine, repetitive Transcranial Magnetic Stimulation (rTMS), transcranial Direct Current Stimulation (tDCS). The use of ECT to treat schizophrenia will also be examined. The research team will partner with clinical service providers and a government health department.
A Randomised Controlled Trial Of Magnetic Seizure Therapy In Major Depressive Disorder
Funder
National Health and Medical Research Council
Funding Amount
$372,049.00
Summary
Electroconvulsive therapy (ECT) is the only established treatment for a substantial sub-population of patients who fail to respond to other therapies. However, there are significant complications of ECT including memory related side-effects. The aim of this study is to evaluate the clinical efficacy of a new form of treatment for severe depression, magnetic seizure therapy, which appears to have a substantially reduced rate of cognitive side-effects.
Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling
Funder
National Health and Medical Research Council
Funding Amount
$347,767.00
Summary
Electroconvulsive therapy (ECT) is the treatment of choice for severe, resistant depression. However it use is reduced by concerns about memory problems. The effectiveness and side effects of ECT depend on how it is given, but clinical trials can only test 1 variation at a time. This study will use sophisticated computational modelling to understand how varying the treatment approach affects clinical outcomes, allowing the development of next-generation, custom-designed ECT treatment.
Role Of Neurogenesis In Clinical Recovery From Depression During ECT: Application Of A Novel In Vivo Magnetic Resonance Spectroscopy Technology
Funder
National Health and Medical Research Council
Funding Amount
$587,478.00
Summary
Neurogenesis refers to the generation of new brain cells, which is now known to continue well into adulthood. On the basis of animal studies, deficiencies in neurogenesis have been implicated in development of depression, and stimulation of neurogenesis proposed as one of the ways that anti-depressants may work. Using the latest technological advances in brain imaging, we will for the first time assess the merit of these theories in humans with depression before and after treatment.
A Controlled Study Of Bilateral Electroconvulsive Therapy
Funder
National Health and Medical Research Council
Funding Amount
$423,257.00
Summary
Electroconvulsive therapy (ECT) is a highly effective treatment for depression, used in Australia and throughout the world to treat severe depression that has not responded to other treatments. Despite clear evidence of its effectiveness as a treatment, the use of ECT is limited by concerns over memory side effects. This study evaluates a new approach to ECT that has the potential to preserve its effectiveness, while greatly reducing effects on memory.
I will determine the efficacy and safety of crystalloid resuscitation fluids in conventional models of care. This is a fundamental and unresolved question in Intensive Care Medicine and will have an impact on clinical practice worldwide. I will also consolidate and enhance a series of projects to provide the next generation of clinician-researchers with high-quality research opportunities. These include projects in sepsis, traumatic brain injury, and endocrine function in critical illness.
Delineating The Role Of Fludrocortisone And Hydrocortisone In The Management Of Patients With Septic Shock
Funder
National Health and Medical Research Council
Funding Amount
$553,664.00
Summary
Sepsis and septic shock are leading causes of morbidity and mortality globally. Steroids have been used to treat septic shock for decades. Two new trials, one using hydrocortisone vs. placebo and another using hydrocortisone plus fludrocortisone vs. placebo have produced differing results, with fludrocortisone possibly conferring a mortality benefit. My Program will investigate this evidence gap by providing critical evidence for the design and execution of a future definitive trial.